EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Multizentrische StudieRandomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Effects of ganaxolone on non-seizure outcomes in CDKL5 Deficiency Disorder: Double-blind placebo-controlled randomized trial

J Downs, P Jacoby, N Specchio, H Cross, S Amin, N Bahi-Buisson, R Rajaraman, B Suter, O Devinsky, A Aimetti, G Busse, H E Olson und 3 weitere

European Journal of Paediatric Neurology · 2024

DOI: 10.1016/j.ejpn.2024.06.005 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift European Journal of Paediatric Neurology, 2024. Verfasst von J Downs und 14 weiteren Autor:innen. Beteiligte Einrichtung: Telethon Kids Institute, The University of Western Australia, Australia; Curtin School of Allied Health, Curtin University, Perth, Australia. Electro…. Hauptthemen laut MEDLINE: Quality of Life. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NINDS NIH HHS, NINDS, Stan Perron Charitable Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

CDKL5 deficiency disorder (CDD) is a rare developmental and epileptic encephalopathy. Ganaxolone, a neuroactive steroid, reduces the frequency of major motor seizures in children with CDD. This analysis explored the effect of ganaxolone on non-seizure outcomes. Children (2-19 years) with genetically confirmed CDD and ≥ 16 major motor seizures per month were enrolled in a double-blind randomized placebo-controlled trial. Ganaxolone or placebo was administered three times daily for 17 weeks. Behaviour was measured with the Anxiety, Depression and Mood Scale (ADAMS), daytime sleepiness with the Child Health Sleep Questionnaire, and quality of life with the Quality of Life Inventory-Disability (QI-Disability) scale. Scores were compared using ANOVA, adjusted for age, sex, number of anti-seizure mediations, baseline 28-day major motor seizure frequency, baseline developmental skills, and behaviour, sleep or quality of life scores. 101 children with CDD (39 clinical sites, 8 countries) were randomized. Median (IQR) age was 6 (3-10) years, 79.2 % were female, and 50 received ganaxolone. After 17 weeks of treatment, Manic/Hyperactive scores (mean difference 1.27, 95%CI -2.38,-0.16) and Compulsive Behaviour scores (mean difference 0.58, 95%CI -1.14,-0.01) were lower (improved) in the ganaxolone group compared with the placebo group. Daytime sleepiness scores were similar between groups. The total change in QOL score for children in the ganaxolone group was 2.6 points (95%CI -1.74,7.02) higher (improved) than in the placebo group but without statistical significance. Along with better seizure control, children who received ganaxolone had improved behavioural scores in select domains compared to placebo.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Quality of LifeAdolescentChildChild, PreschoolFemaleHumansMaleYoung AdultDouble-Blind MethodEpileptic SyndromesPregnanoloneSeizuresSpasms, InfantileTreatment Outcome

Stichwörter der Autor:innen

Anti-Seizure medicationCDKL5 deficiency disorderEpilepsyPatient-reported outcomes

Substanzen

ganaxolonePregnanolone

Autor:innen und Institutionen

  • Telethon Kids Institute, The University of Western Australia, Australia; Curtin School of Allied Health, Curtin University, Perth, Australia. Electronic address: Jenny.Downs@telethonkids.org.au.
  • Telethon Kids Institute, The University of Western Australia, Australia.
  • Rare and Complex Epilepsy Unit, Department of Neuroscience, Bambino Gesù Children's Hospital IRCCS, Full Member of European Reference Network EpiCARE, Rome, Italy.
  • UCL Great Ormond Street Institute of Child Health, London, United Kingdom.
  • Department of Paediatric Neurology, Bristol Royal Hospital for Children, Bristol, United Kingdom.
  • Pediatric Neurology, Necker Enfants Malades, Université de Paris, Paris, France.

Förderung

  • NINDS NIH HHS
  • NINDS
  • Stan Perron Charitable Foundation
  • Marinus Pharmaceuticals Inc

Zitieren

APA

Downs, J., Jacoby, P., Specchio, N., Cross, H., Amin, S., Bahi-Buisson, N., Rajaraman, R., Suter, B., Devinsky, O., Aimetti, A., Busse, G., Olson, H. E., Demarest, S., Benke, T. A., & Pestana-Knight, E. (2024). Effects of ganaxolone on non-seizure outcomes in CDKL5 Deficiency Disorder: Double-blind placebo-controlled randomized trial. European Journal of Paediatric Neurology. https://doi.org/10.1016/j.ejpn.2024.06.005

Vancouver

Downs J, Jacoby P, Specchio N, Cross H, Amin S, Bahi-Buisson N, et al. Effects of ganaxolone on non-seizure outcomes in CDKL5 Deficiency Disorder: Double-blind placebo-controlled randomized trial. European Journal of Paediatric Neurology. 2024. doi:10.1016/j.ejpn.2024.06.005

BibTeX
@article{Downs2024,
  author = {Downs, J and Jacoby, P and Specchio, N and Cross, H and Amin, S and Bahi-Buisson, N and Rajaraman, R and Suter, B and Devinsky, O and Aimetti, A and Busse, G and Olson, H E and Demarest, S and Benke, T A and Pestana-Knight, E},
  title = {Effects of ganaxolone on non-seizure outcomes in CDKL5 Deficiency Disorder: Double-blind placebo-controlled randomized trial},
  journal = {European Journal of Paediatric Neurology},
  year = {2024},
  doi = {10.1016/j.ejpn.2024.06.005}
}
Kostenlos starten →